Mijten Bencard (Dermatophagoides Pteronyssinus)

The Dermatophagoides pteronyssinus extract in Mijten Bencard is administered cutaneously in gradually increasing doses. This exposure stimulates regulatory T‑cells, shifts the immune response away from a Th2‑dominant IgE profile, lowers specific IgE, raises IgG4 blocking antibodies, and reduces mast‑cell activation, thereby decreasing allergic inflammation.

The dosing regimen for Mijten Bencard is individualized. A qualified prescriber determines the starting concentration, escalation schedule, and maintenance dose based on the patient’s age, severity of allergy, and clinical response. No standard dose can be quoted without a medical prescription.

Safety data for Mijten Bencard in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mijten Bencard. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Mijten Bencard is a standardized Dermatophagoides pteronyssinus extract delivered cutaneously, whereas some alternatives are sublingual tablets or extracts from multiple mite species. Its formulation focuses on precise dosing and cold‑chain stability, offering clinicians a controlled method to induce tolerance, while comparative efficacy depends on individual patient response and the specific product’s allergen profile.

Mijten Bencard must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. Maintaining the cold chain preserves the biological activity of the allergen extract.

The product is administered by a healthcare professional via subcutaneous injection into the skin. The initial dose is low and is gradually increased according to a schedule defined by the prescriber, with regular monitoring for local or systemic reactions during the build‑up and maintenance phases.

The most serious adverse events are systemic allergic reactions, including anaphylaxis, severe bronchospasm, and angioedema that can compromise the airway. Immediate medical attention is required if any signs of a systemic reaction appear after injection.

Mijten Bencard is contraindicated in patients with uncontrolled severe asthma, known hypersensitivity to the extract or any excipients, children younger than five years, and individuals receiving beta‑blocker therapy who cannot be closely monitored for anaphylaxis.